Cardiff Oncology(US:CRDF) Globenewswireยท2025-06-17 20:05Core Points - Cardiff Oncology, Inc. has appointed Dr. Roger Sidhu as Chief Medical Officer, succeeding Dr. Fairooz Kabbinavar, who will remain in an advisory role [1][2] - The company plans to share additional clinical data from its lead program in RAS-mutated metastatic colorectal cancer (mCRC) on July 29, 2025 [1][2][5] - Dr. Sidhu brings over 20 years of experience in oncology research and development, having previously held significant roles at Treadwell Therapeutics and Amgen [2][3][4] Company Overview - Cardiff Oncology is a clinical-stage biotechnology company focused on developing novel therapies through PLK1 inhibition for various cancers, with its lead asset being onvansertib [1][8] - The company is targeting RAS-mutated mCRC and has ongoing and planned trials for other indications, including metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple-negative breast cancer [8] Leadership Transition - Dr. Sidhu's appointment is seen as a strategic move to advance the clinical program for onvansertib through late-stage development [2][6] - The company expressed gratitude to Dr. Kabbinavar for his leadership in progressing onvansertib's clinical development across multiple tumor types [2] Upcoming Events - Cardiff Oncology will host a conference call and live webcast on July 29, 2025, to present additional clinical data from the CRDF-004 trial [5][6] - The conference call will be accessible via the company's website, with a replay available afterward [5] Stock Option Grant - In connection with Dr. Sidhu's appointment, the Board of Directors approved a grant of non-qualified stock options to purchase 600,000 shares of common stock, with an exercise price of $3.86 per share [6][7] - The stock options will vest over four years, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months [7]